Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

Solid, Early Surgical Results With Polymer Mitral Valve

News Conference News NY Valves 2025

Solid, Early Surgical Results With Polymer Mitral Valve

July 02, 2025

Second Annual STS Compensation Survey Finds Gaps Persist By Gender

News Conference News STS 2025

Second Annual STS Compensation Survey Finds Gaps Persist By Gender

Yael L. Maxwell

January 28, 2025

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

News Conference News STS 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

Yael L. Maxwell

February 09, 2024

STS Survey Identifies Stark Gender Disparities in Compensation

News Conference News STS 2024

STS Survey Identifies Stark Gender Disparities in Compensation

Yael L. Maxwell

January 30, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

News Conference News TVT 2022

Less Paravalvular Leak With Newer Acurate neo2 TAVI: Registry

Michael O'Riordan

June 13, 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

April 02, 2022

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

News Conference News TCT 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

October 16, 2020

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

News Conference News TCT 2020

Global EXPAND: Next-Gen MitraClip Cuts MR, Boosts QoL at 1 Year

October 16, 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

News Conference News ACC 2020

PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients

Yael L. Maxwell

March 29, 2020

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

News Conference News CRT 2020

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

Michael O'Riordan

February 27, 2020

Signal of Impaired Sapien XT Durability in Midterm Follow-up

News Conference News PCR London Valves 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Michael O'Riordan

November 20, 2019

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

News Conference News TCT 2019

COAPT at 3 Years: Crossover Patients See Benefits From MitraClip

September 28, 2019

Surgical Volume Matters When It Comes to Repair of Primary MR

News Conference News TCT 2019

Surgical Volume Matters When It Comes to Repair of Primary MR

September 28, 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

News Conference News TCT 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

September 27, 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.